Hand-out
Press Releases
Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)
To date, laru-zova has been well-tolerated by all participants in the Phase 2 DAWN study.Data show promising early improvements in low luminance visual acuity (LLVA), a critical measure of visual
